Dementia, of which Alzheimer’s is the most common form, affects close to 50 million people worldwide and is expected to affect more than 131 million by 2050, according to the non-profit campaign group Alzheimer’s Disease International. But these tests are invasive, expensive and may only show results when the disease has already started to progress. Despite decades of scientific research, there is no treatment that can slow the progression of Alzheimer‘s. And that’s where the real value in this test will come,” said Colin Masters, a professor at the University of Melbourne who co-led the research. John Hardy, a professor of neuroscience at University College London, said it was a “hopeful study which could have a very positive impact on diagnostic accuracy.”

Source: bd News24 February 01, 2018 10:41 UTC